Keymed Biosciences, Inc. (HK:2162) has released an update.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Keymed Biosciences Inc. has announced promising results from an exploratory clinical study of their drug CM313 in treating primary immune thrombocytopenia, published in The New England Journal of Medicine. The study showed that 95.5% of patients achieved a significant increase in platelet counts with a well-tolerated safety profile, indicating rapid and sustained efficacy. The drug is also under investigation for other conditions such as multiple myeloma and systemic lupus erythematosus.
For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.